AI Summary
We reviewed 6 live results for epyztek (ustekinumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Biosimilars.
Comparison Table
Recommended
Epyztek (ustekinumab)
Source: Samsung Bioepis
Description
Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara.
Best for
patients in South Korea, psoriasis treatment and local biosimilar seekers
View Details
Rating
Pyzchiva (Ustekinumab)
Source: Samsung Bioepis
Description
Pyzchiva is an immunology biosimilar for the treatment of autoimmune disorders such as Crohn’s disease and psoriasis.
Best for
Crohn’s disease, psoriasis treatment and immunology patients
View Details
Rating
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
| Compare | Epyztek (ustekinumab) | Pyzchiva (Ustekinumab) | Steqeyma (ustekinumab biosimilar) |
|---|---|---|---|
| Source | Samsung Bioepis | Samsung Bioepis | Celltrion Healthcare |
| Description | Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara. | Pyzchiva is an immunology biosimilar for the treatment of autoimmune disorders such as Crohn’s disease and psoriasis. | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). |
| Best for | patients in South Korea, psoriasis treatment and local biosimilar seekers | Crohn’s disease, psoriasis treatment and immunology patients | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Epyztek (ustekinumab) from Samsung Bioepis."
I picked this because Epyztek offers South Korean patients a reliable, locally developed biosimilar option for treating severe inflammatory conditions with established safety profiles.
Share this search
Related Finds